1. CORESTA Meeting, Agronomy/Phytopathology, 2019, Victoria Falls, AP Sustainability Forum

    Agro-Phyto Sustainability Forum

    WILDE L.(1); PRIBIC V.(2); EVANS W.(3); ROYO E.(4); BARGIACCHI E.(5)
    (1) twentyfifty Ltd, Frome, U.K.; (2) JT International S.A., Geneva, Switzerland; (3) Imperial Tobacco Limited, Durban, South Africa; (4) Philip Morris International, Cape Town, South Africa; (5) Consortium INSTM, Firenze, Italy
    In 2015, the United Nations published 17 sustainable development goals and their corresponding targets to be achieved by 2030. Like other sectors, the tobacco and alternative product sectors are likely to impact most of the goals. Consequently, it is ...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 32

    Enumeration of TBNK cells: A case for a bioanalytical assay to support clinical studies for the development of modified risk tobacco products

    NEWLAND K.; MILLER P.; FARMEN R.
    Celerion, Inc., Lincoln, NE, U.S.A.
    Smoking has been reported to lessen the body’s immune response making it more susceptible to infections. Chronic cigarette smoke exposure causes imbalance in immune homeostasis affecting the circulating immune cells. Peripheral blood lymphocytes are ...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 49

    The CORESTA in vitro test battery for combustible tobacco products: update from the 2004 Rationale and Strategy Report

    LEE K.M.(1); JORDAN K.G.(2); WIECZOREK R.(3); MOENNIKES O.(4); CLEMENTS J.(5); CROOKS I.(6); HASHIZUME T.(7); MILLER J.(8); WEBER E.(9); YOSHINO K.(7)
    (1) Altria Client Services, Richmond, VA, U.S.A.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.; (3) Imperial Brands, Reemtsma Cigarettenfabriken GmbH, Hamburg, Germany; (4) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (5) Covance Laboratories Ltd, Harrogate, U.K.; (6) British American Tobacco (Investments) Ltd, R&D, Southampton, U.K.; (7) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (8) JT International SA, Geneva, Switzerland; (9) Ökolab, Vienna, Austria
    In 2004, the CORESTA In Vitro Toxicity Task Force issued a rationale and strategy report, commonly known as “the CORESTA in vitro test battery guideline”. The goals of this guideline were to: 1) develop the rationale and strategy for conducting in vitro ...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 58

    A consortium approach for consumer-reported outcome measures to assess tobacco- and nicotine-containing products

    ACQUADRO C.(1) on behalf of the CORESTA CROM Task Force: AYALA-FIERRO F.(2); BLACK R.(3); CAHOURS X.(4); CHREA C.(5); CURTIN G.(6); GILES L.(7); McCAFFREY S.(3); PARK C.H.(8); PRASAD K.(9); SHERWOOD N.(10); SHIFFMAN S.(11); SMITH J.(6); SPIES E.(5)
    (1) Mapi Research Trust, Lyon, France; (2) ITG Brands, Greensboro, NC, U.S.A.; (3) Altria Client Services, Richmond, VA, U.S.A.; (4) SEITA - Imperial Brands, Paris, France; (5) Philip Morris Products S.A., Neûchatel, Switzerland; (6) RAIS, Winston-Salem, NC, U.S.A.; (7) JT Int'l SA, Genève, Switzerland; (8) KT&G Research Institute, Daejeon, Republic of Korea; (9) British American Tobacco, Southampton, U.K.; (10) Neil Sherwood Consulting, Commugny, Switzerland; (11) Pinney Associates, Pittsburgh, PA, U.S.A.
    In the tobacco space, consumer-reported outcome measures (CROM) are essential for understanding motivations, subjective effects, and behavior. Such measures have become particularly important with the advent of candidate modified risk tobacco products ...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 60

    Can we still observe a net health benefit due to the introduction of modified-risk tobacco products (MRTPs) should the illegal trade in counterfeit cigarettes increase? A model perspective.

    LARROQUE S.; CHARRIERE M.; MEGER M.
    JT International SA, Geneva, Switzerland
    Since 2012 and the publication of the MRTP guidance by the U.S. FDA encouraging the use of computational modelling, many robust dynamic models have been developed that are projecting net health benefits in the whole population after introduction of ...
  6. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 17

    A clinical study investigating changes in exposure to cigarette smoke chemicals in U.K. smokers who switch to using a tobacco heating product for a five-day period

    McEWAN M.(1); EBAJEMITO J.K.(1); GALE N.(1); ELDRIDGE A.(1); CAMACHO O.M.(1); MURPHY J.(1); HARDIE G.(1); PROCTOR C.J.(1)
    (1) British American Tobacco (Investments) Limited, R&D, Southampton, U.K.; (2) Celerion Inc., Lincoln, NE, U.S.A.
    Smoking is a leading cause of numerous diseases, particularly lung cancer, chronic obstructive pulmonary disease and cardiovascular diseases. Consequently, there is a recognized need to provide smokers with alternative nicotine-delivery devices that have ...
  7. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 44

    Time and spatially resolved in-situ determination of temperature, pressure and gas phase concentration of selected smoke constituents inside a burning superslim cigarette. Part I – Thermophysical mapping

    CUI Huapeng(1); EHLERT S.(2); XIE Fuwei(1); DENG Nan(1); LI Bin(1); LIU Chuan(3); McADAM K.(3); WALTE A.(2); ZIMMERMANN R.(2)
    (1) Zhengzhou Tobacco Research Institute of CNTC, Zhengzhou, Henan, P.R. China; (2) Photonion GmbH, Schwerin, Germany; (3) British American Tobacco (Investments) Limited, Global R&D, Southampton, U.K.
    Superslim cigarettes in China are a relevant product category on the market. Accurate determination of key thermo-physical and-chemical parameters in superslim cigarettes are essential for the mechanistic understanding of combustion as well as pyrolysis ...
  8. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 59

    An inter-laboratory comparison study focused on the determination of total NNAL in human urine

    NEWLAND K.(1); SCHERER M.(2); HECHT S.S.(3); TROUDE V.(4); PRASAD G.L.(5)
    (1) Celerion Inc., Lincoln, NE, U.S.A.; (2) ABF GmbH, Planegg, Germany; (3) University of Minnesota Cancer Center, Minneapolis, MN, U.S.A.; (4) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (5) RAI Services Company, Winston-Salem, NC, U.S.A.
    In an ongoing effort to fulfil the second objective of the CORESTA Biomarker Sub-Group, periodic inter-laboratory comparison studies have been performed to evaluate the consistency of the quantitation for various harmful or potentially harmful exposure ...